All In Biotech

Drug Trial Radar · NCT07142980

A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

A Phase I Study of HRS-7172 Evaluating Safety, Tolerability and Pharmacokinetics in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 12, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.

Conditions

  • Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Interventions

  • HRS-7172 TabletsDrug

    HRS-7172 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs)Time frame: From screening period up to 30 days after the last dose.
  2. Incidence and severity of serious adverse events (SAEs)Time frame: From screening period up to 30 days after the last dose.
  3. Dose-limiting toxicity (DLT)Time frame: From day 1 to day 24.
  4. Maximum tolerated dose (MTD)Time frame: From day 1 to day 24.
  5. Recommended Phase II Dose (RP2D)Time frame: From day 1 to day 24.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Affiliated Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.